Wednesday, February 27, 2013 - Thursday, February 28, 2013
7:00 a.m. - 5:00 p.m.
Add to Calendar
Monday, February 25, 2013 12:00 p.m.
Where The Lodge at Torrey Pines
11480 North Torrey Pines Road
La Jolla, California 92037
Online registration has now closed. On-site registration will open up on Wednesday, February 27th at 7:30 AM in the Maurice Braun foyer.
The Premier Partnering Event of 2013
BIOCOM's Third Annual Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives and business development professionals from leading pharmaceutical and biotech companies.
The conference will include case study presentations, individual company presentations, one-on-one meetings, and numerous networking opportunities.
Alain Baron, President & CEO, Director, Elcelyx Therapeutics
Miranda Biven, Partner, Wilson Sonsini Goodrich & Rosati
Richard Brudnick, Vice President of Business Development, Biogen-Idec
Tom Bumol, President/Site Head at AME, Eli Lilly and Company
Dan Burgess, President & CEO,Rempex Pharmaceuticals
Iain Dukes, Vice President, External Research and Development, Amgen
Lewis Geffen, Co-Chair, VC and Emerging Companies Practice, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo
George S. Golumbeski, Senior Vice President Business Development, Celgene Corporation
Corey Goodman, Partner, venBio LLC
Kurt Graves, Chairman & CEO, Intarcia Therapeutics, Inc.
Richard Heyman, President and CEO, Aragon Pharmaceuticals
David Kabakoff, Executive Partner, Sofinnova
Adam Keeney, VP, Head of Transactions, Johnson & Johnson West Coast Innovation Centers
Rick Lindberg, Executive Director and Site Head, Centers for Therapeutic Innovation, California, Pfizer Inc.
Brian McVeigh, Vice President, WWBD Transactions and Investment Management, GlaxoSmithKline Pharmaceuticals
Ronald C. Newbold, Vice President - Strategic Research Partnerships, External R&D Innovation, Worldwide Research & Development, Pfizer, Inc.
Terence G. Porter, Vice President, Search & Evaluation, Global Business Development, Takeda Pharmaceuticals International, Inc.
Bill Rastetter, Chairman, Illumina; Chairman, Neurocrine Biosciences; Chairman, Fate Therapeutics; Chairman, Receptos, Inc.
John C. Reed, Professor and Donald Bren Chief Executive Chair, Former Chief Executive Officer, Sanford-Burnham Medical Research Institute
Tony Rosenberg, Head of Global BD & Licensing, Novartis Pharma
Michael Ross, Managing Partner, SV Life Sciences
Jim Schaeffer, Executive Director of Licensing & External Research, Merck Research Labs
Susan Schaeffer, Editor, BioCentury, The Bernstein Report on BioBusiness
Jamie Topper, General Partner, Frazier Healthcare
Gonul Velicelebi, Founder, President & CEO, CalciMedica
Mark Wiggins, SVP, Business Development, Elcelyx Therapeutics
Rob Wills, Vice President, Alliance Management, Johnson & Johnson
Kleanthis Xanthopoulos, President and CEO, Regulus Therapeutics
Barbara Yanni, Vice President and Chief Licensing Officer, Merck
Planner Ashleigh Berry